Plain-English translation of NCT03593317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help slow or prevent damage to the right side of your heart if you have arrhythmogenic right ventricular dysplasia (ARVD), a rare inherited heart condition. Right now, there's no proven treatment that stops the heart tissue from gradually being replaced by scar tissue and fat. Researchers hope this medication might protect your heart and reduce dangerous irregular heartbeats.
People with ARVD currently only receive treatment for irregular heartbeats after they happen, but there's nothing proven to prevent the underlying heart damage from getting worse. This study exists to find out if this medication can actually slow that damage down and help patients live better, longer lives.
You likely qualify if…
You likely don't qualify if…
You will take a daily pill for 3 years—either the study medication or a placebo (dummy pill), decided by chance. Half the participants will get each treatment, and neither you nor the doctors will know which one you're taking. You'll visit the clinic several times over those 3 years (at 6 months, 1 year, and 3 years) for heart tests like ECGs, heart imaging, blood work, and monitoring of your heartbeat patterns to see how you're doing.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
France